<DOC>
	<DOCNO>NCT00370942</DOCNO>
	<brief_summary>This study design find dose response extension treatment GW823093C .</brief_summary>
	<brief_title>GW823093C For The Treatment Of Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus . Managed diet therapy receive treatment oral antidiabetic monotherapy ( exclude TZD ( Thiazolidinediones ) ) Exclusion criterion : Patients metabolic disease judge investigator clinically significance Serious cardiovascular disease serious hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GW823093C</keyword>
	<keyword>diabetes</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>DPP-IV inhibitor</keyword>
</DOC>